Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

An oral, liver-restricted LXR inverse agonist for dyslipidemia: preclinical development and phase 1 trial.

Name: Kaimen Rigor review — An oral, liver-restricted LXR inverse agonist for dyslipidemia: preclinical development and phase 1 trial.
Item: An oral, liver-restricted LXR inverse agonist for dyslipidemia: preclinical development and phase 1 trial.
Rating: 59
Author: Alpha1

Li X, Benegiamo G, Vijayakumar A, Sroda N, Kimura M, Huss RS, Weng S, Murakami E, Kirby BJ, von Alvensleben GVG, Kremoser C, Gane EJ, Takebe T, Myers RP, Subramanian GM, Auwerx J

Paper source

Read full text (PMC)

Embed this Rigor badge

Kaimen Rigor review — 1★ (Critical), 0 critical, 6 high issues for “An oral, liver-restricted LXR inverse agonist for dyslipidemia: preclinical development and phase 1 trial.”

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 10, 2026

Read alongside

An oral, liver-restricted LXR inverse agonist for dyslipidemia: preclinical development and phase 1 trial.

Li X, Benegiamo G, Vijayakumar A, Sroda N, Kimura M, Huss RS, Weng S, Murakami E, Kirby BJ, von Alvensleben GVG, Kremoser C, Gane EJ, Takebe T, Myers RP, Subramanian GM, Auwerx J

Read full text (PMC)

DOI

10.1038/s41591-025-04169-6

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/b029c5f1-725e-4936-835a-17129b2d08b3" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/b029c5f1-725e-4936-835a-17129b2d08b3/badge" alt="Kaimen Rigor review — 1★ (Critical), 0 critical, 6 high issues for “An oral, liver-restricted LXR inverse agonist for dyslipidemia: preclinical development and phase 1 trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

2a73b286fe4107c51fb52e9f314000eba38190a51ddc360d0311407ce202d970

Verify via API

Issued Aug 10, 2026Engine 7.29.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Alpha¹ by Kaimen

Fetching the latest research

Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

An oral, liver-restricted LXR inverse agonist for dyslipidemia: preclinical development and phase 1 trial.

Li X, Benegiamo G, Vijayakumar A, Sroda N, Kimura M, Huss RS, Weng S, Murakami E, Kirby BJ, von Alvensleben GVG, Kremoser C, Gane EJ, Takebe T, Myers RP, Subramanian GM, Auwerx J

Paper source

An oral, liver-restricted LXR inverse agonist for dyslipidemia: preclinical development and phase 1 trial.

Read full text (PMC)

Embed this Rigor badge

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 10, 2026

Kaimen Rigor review

Kaimen Rigor reviewed

1 / 5

Critical — serious problems across many checks

Mixed Methods

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×4−2★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ReportingBiological variables not met−0.5★
ReportingKey resources not met−0.5★
ReportingStudy design partially met−0.25★
ReportingEthical approvals partially met−0.25★

Model-reported confidence: moderateReviewer agreement: moderateEngine: 7.29.0Source: full text

Not verified in this report

References were not verified against Crossref/OpenAlex.
Statistics were not checked: no recomputable values were found in this text — no test statistic reported with its degrees of freedom, no effect estimate printed with both a 95% CI and a p-value, and no percentage printed with both its count and its denominator.

Biggest issues

01Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The efficacy claim is based on reduction in plasma lipids (TG, RC, LDL-C) which are surrogate biomarkers. The paper shows target engagement (reduction in LXR target genes, ApoC3, ANGPTL3) but does not cite validated evidence that these lipid changes are linked to improved clinical outcomes (e.g., reduced cardiovascular events).
“TLC-2716 treatment for 14 days led to dose-dependent improvements in plasma TG and RC and other atherogenic lipids”
Find in source
02Biological variables not reported
highDisclosurereviewer-assessedFull detail
Biological variables are inadequately reported across both preclinical and clinical components, with no sub-criterion fully met due to missing details on animal sex, age, housing, and human demographics.
03Key resources not identified
highDisclosurereviewer-assessedFull detail
Key biological resources are inadequately identified; only software tools are fully reported, while cell line authentication, mycoplasma testing, and reagent identification are lacking.
“PK parameters were estimated via noncompartmental methods using Pheonix WinNonlin 6.2.1 and 8.3.4 (Certara).”
Statistical analysisFind in source
04Other integrity concern
mediumAuthenticityreviewer-assessedFull detail
Trial NCT06564584 was first submitted to ClinicalTrials.gov on 2024-08-19, after the registered study start date of 2024-08-12. Retrospective registration means the protocol and outcomes were not on the public record before the study ran, which is what prospective registration exists to establish.
NCT06564584
reviewer’s wording
05Other integrity concern
mediumAuthenticityreviewer-assessedFull detail
Cell line "HepG2" is on the ICLAC register (CURATED-0001) as misidentified (Liver, hepatoblastoma), not Liver, hepatocellular carcinoma. Results attributed to this line may describe a different cell type unless the stock was authenticated (e.g. STR profiling).
“1 and SREBP1c luciferase reporter assays HT-29 or HepG2 cells were stably transfected with pGL4 luciferase reporter plasmid c”
Find in source

Findings by category

101ArithmeticNumerical inconsistencies 202OverreachOverstated conclusions 103AuthenticityData authenticity concerns 404DisclosureReporting gaps 05AvailabilityNone found 06Copyedit7 minor suggestions

This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

The paper presents a well-founded scientific premise and robust statistical analysis, with transparent reporting of the clinical trial and data availability. However, significant reporting gaps exist in study design (randomization, blinding), biological variables (animal age/housing, human race/ethnicity, sex justification), ethical approvals (missing animal IACUC), and key resources (cell line authentication, mycoplasma testing, antibody details).

All eight dimensions were evaluated. Reviewers generally agreed on the 'pass' dimensions, but diverged on the 'warn' dimensions, particularly regarding the extent of missing information in preclinical studies. The synthesis weighed the specific evidence provided by each reviewer, prioritizing concrete omissions over general statements. The statistics component's coverage was limited to recomputing a subset of reported tests, and citation verification was limited to retracted or non-existent references.

Numerical inconsistencies

1 finding · worst low

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Overstated conclusions

2 findings · worst high

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Conclusions only partially backed by the presented evidenceAssessed

12 major claims checked against the paper's own evidence: all adequately supported.

Premise concern: surrogate not validated for clinical benefit.

Data authenticity concerns

1 finding · worst medium

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Other integrity concernAssessed

4 integrity concerns flagged (0 high).

Reporting gaps

4 findings · worst high

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Biological variables not reportedAssessed
Key resources not identifiedAssessed
Ethics/consent reporting incompleteAssessed
Study-design details incomplete (controls, blinding, power)Assessed

Eight Dimensions4 pass · 2 warn · 2 fail

The paper extensively cites prior research on LXR biology, dyslipidemia, and the limitations of LXR agonists, establishing a clear rationale for developing a liver-restricted inverse agonist. The hypothesis follows logically from the cited evidence, and the authors specifically address how their approach mitigates prior limitations (systemic side effects, lack of clinical testing).

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 90% conf

The premise that LXR repression can reduce atherogenic lipids is well established through extensive prior literature, and the study explicitly identifies the key limitation (risk of impaired reverse cholesterol transport) that its liver/gut-restricted compound is designed to address.

Evidence

“Given concerns that systemic LXR repression may impair reverse cholesterol transport, we developed TLC-2716, an orally administered, gut- and liver-restricted LXR inverse agonist.”

AbstractFind in source

“However, to date, no LXR inverse agonist has been evaluated in humans.”

IntroductionFind in source

paraphrase[Introduction]

“Paraphrase: The introduction cites numerous prior studies on LXR activation raising TG/LDL-C, LXR inverse agonists in preclinical models, and the risk of impaired RCT.”

PASSReviewer 2· 90% conf

The scientific foundation is well established: prior work on LXR biology, hypertriglyceridemia and the failure of LXR agonists is cited, the rationale for an LXR inverse agonist is logically developed, and prior limitations are acknowledged.

Evidence

paraphrase[Introduction, paragraph 2]

“Repression of LXR systemically carries potential risks, including the impairment of reverse cholesterol transport (RCT)... which could promote atherogenesis”

“However, to date, no LXR inverse agonist has been evaluated in humans.”

Introduction ¶3Find in source

PASSReviewer 3· 95% conf

The scientific premise is well-established with thorough citations of prior work, a clear logical rationale for the study, and explicit acknowledgment of limitations of prior approaches.

Evidence

paraphrase[Introduction, paragraph 5]

“LXR activation increases liver and plasma TG and LDL-C in animal models and humans by upregulating DNL genes... By contrast, repression of LXR activity in the liver reduces hepatic DNL...”

“Given concerns that systemic LXR repression may impair reverse cholesterol transport, we developed TLC-2716, an orally administered, gut- and liver-restricted LXR inverse agonist.”

Introduction ¶6Find in source

paraphrase[Abstract]

“LXR repression can reduce plasma TG and cholesterol and improve insulin sensitivity by suppressing de novo lipogenesis and intestinal lipid absorption and enhancing clearance of TG-rich lipoproteins.”

For the human trial, randomization is stated ('Participants were randomized...') but no method (RNG/block/stratified) is given; randomization unit (participant) is clear. No blinding statement appears anywhere in the methods. The paper explicitly states 'no formal power or sample size calculations were used to determine the sample size for this study.' Inclusion/exclusion criteria are detailed, and the Hodges–Lehmann estimator was deliberately used to handle skewed data/outliers, which serves as the outlier/analysis-population approach. Preclinical animal studies likewise report no randomization or blinding.

Sub-criteria

controlsN/A

power analysisINADEQUATE

blinding levelsNOT REPORTED

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodINADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (3) — the votes behind the verdict

WARNReviewer 1· 60% conf

The phase 1 trial is randomized and placebo-controlled with detailed inclusion/exclusion criteria and an explicit exploratory rationale for the absence of a formal power calculation, but randomization method and blinding are not reported.

Evidence

“Participants were randomized to receive either placebo (two participants per dose) or TLC-2716 0.5, 2, 6 or 12 mg (eight participants per dose) orally once daily for 14 days.”

MethodsFind in source

“Due to its exploratory nature, no formal power or sample size calculations were used to determine the sample size for this study.”

Statistical analysisFind in source

absence[Methods, Phase 1 clinical trial]

Blinding is not reported anywhere in the manuscript.

WARNReviewer 2· 80% conf

The phase 1 trial reports randomization and detailed inclusion/exclusion criteria and an outlier-robust analysis, but randomization method, blinding, and a priori power calculation are not described (power explicitly waived for this exploratory phase 1 study).

Evidence

“Participants were randomized to receive either placebo (two participants per dose) or TLC-2716 0.5, 2, 6 or 12 mg (eight participants per dose) orally once daily for 14 days.”

MethodsFind in source

“Due to its exploratory nature, no formal power or sample size calculations were used to determine the sample size for this study.”

Statistical analysisFind in source

“Given the skewed distribution of plasma lipid data, we applied the Hodges–Lehmann estimator in deriving placebo-adjusted percentage change from baseline values in lipid parameters.”

Statistical analysisFind in source

FAILReviewer 3· 85% conf

The study design is inadequately reported across multiple key rigor criteria, including randomization method, blinding, power analysis, and outlier handling, with only 2 of 9 applicable sub-criteria met.

Evidence

“The randomized, placebo-controlled phase 1 study included SAD and MAD cohorts.”

MethodsFind in source

absence[Methods, Phase 1 clinical trial]

No blinding is mentioned for the clinical trial.

“Due to its exploratory nature, no formal power or sample size calculations were used to determine the sample size for this study.”

Statistical analysisFind in source

For the clinical trial, sex and age are reported, but race/ethnicity is not; for preclinical studies, sex is not consistently reported (only toxicology mentions both sexes), age/weight are not reported, species/strain are partially reported, and housing conditions are absent. The single-sex animal studies lack justification. No sub-criterion is fully adequate across the whole study.

Sub-criteria

demographicsNOT REPORTED

sex reportedINADEQUATE

sex justifiedNOT REPORTED

age weight healthINADEQUATE

housing conditionsNOT REPORTED

species strain sourceINADEQUATE

Per reviewer (3) — the votes behind the verdict

WARNReviewer 1· 60% conf

Species/strains and human age/sex/BMI are reported, but animal age/weight, housing conditions, and sex justification for the predominantly male rodent efficacy studies are not described, and human race/ethnicity is absent.

Evidence

paraphrase[Methods, Inclusion and exclusion criteria]

“eligible study participants were healthy, nonsmoking men and women between 18 and 55 years of age and with a BMI from 19 to 35 kg m-2”

paraphrase[Results / Methods]

“Paraphrase: Rodent models are identified as HFD-DIO mice, HFD-fed ZDF rats, HFD-fed SD rats, Wistar Han rats, CD-1 mice, PXB humanized-liver mice, and cynomolgus monkeys.”

absence[Methods]

Animal housing/husbandry conditions and age/weight are not reported.

PASSReviewer 2· 75% conf

Sex, age and BMI of human participants are reported with both sexes enrolled; demographics omit race/ethnicity, and sex was not used in the analysis due to small group sizes.

Evidence

paraphrase[Methods, Inclusion and exclusion criteria]

“eligible study participants were healthy, nonsmoking men and women between 18 and 55 years of age and with a BMI from 19 to 35 kg m−2”

“In this clinical trial study, sex is self-reported. Due to the small sample size of each group, sex is not considered in the analysis.”

Statistical analysisFind in source

FAILReviewer 3· 70% conf

Biological variables are inadequately reported across both preclinical and clinical components, with no sub-criterion fully met due to missing details on animal sex, age, housing, and human demographics.

Evidence

paraphrase[Fig. 4b,c]

“Baseline characterization of healthy participants enrolled in SAD and MAD cohorts... Male, n (%)”

paraphrase[Methods, Phase 1 clinical trial, Inclusion and exclusion criteria]

“eligible study participants were healthy, nonsmoking men and women between 18 and 55 years of age and with a BMI from 19 to 35 kg m−2”

absence[Methods, Animal experiments]

Housing conditions for animals are not reported.

The clinical trial has a named ethics committee approval (Northern B Health and Disability Ethics Committee) and written informed consent. Regulatory compliance is stated for both human (Declaration of Helsinki) and animal (Guide for the Care and Use of Laboratory Animals) studies. However, the specific IACUC approval for animal experiments is not reported in the provided text, despite the description of animal studies.

Sub-criteria

iacuc statementNOT REPORTED

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (3) — the votes behind the verdict

WARNReviewer 1· 65% conf

The human trial has a named approving ethics committee with protocol number and documented written informed consent, but the animal studies lack any IACUC/animal-welfare approval statement, and the human regulatory-compliance statement is generic.

Evidence

“The study protocol was approved by the Northern B Health and Disability Ethics Committee (2022 FULL 12858).”

MethodsFind in source

“Written informed consent was obtained before enrollment.”

MethodsFind in source

absence[Methods, Preclinical studies]

No animal-welfare (IACUC) approval statement is present for the rodent/NHP studies.

WARNReviewer 2· 80% conf

The human trial ethics approval (named committee with protocol number) and written informed consent are documented, but no animal-welfare (IACUC) statement is reported for the extensive preclinical studies, and regulatory compliance is described only generically.

Evidence

“The study protocol was approved by the Northern B Health and Disability Ethics Committee (2022 FULL 12858).”

MethodsFind in source

“Written informed consent was obtained before enrollment.”

MethodsFind in source

“conducted at a single site in New Zealand (Auckland Clinical Research) from 27 July 2022 to 18 June 2023, in accordance with relevant local regulatory policies.”

MethodsFind in source

WARNReviewer 3· 90% conf

Human ethics and consent are adequately reported, but the animal IACUC statement is missing, which warrants a warning.

Evidence

“The study protocol was approved by the Northern B Health and Disability Ethics Committee (2022 FULL 12858).”

MethodsFind in source

“Written informed consent was obtained before enrollment.”

MethodsFind in source

absence[Methods, Animal experiments]

IACUC approval for animal experiments is not stated.

The investigational drug TLC-2716 is named but not fully identified with vendor/catalog number; cell lines (iPS-derived HLOs) are not authenticated; mycoplasma testing is not reported; animal species/strains are partially reported without source details; software tools are adequately identified. This results in only 1 of 5 applicable sub-criteria being adequate.

Sub-criteria

mycoplasma testingNOT REPORTED

reagents identifiedINADEQUATE

organisms identifiedINADEQUATE

antibodies identifiedN/A

cell line authenticationNOT REPORTED

software tools identifiedADEQUATE

Per reviewer (3) — the votes behind the verdict

WARNReviewer 1· 55% conf

The investigational product, organsims, primers, and analysis software are identified with versions, and the HLO RNA-seq is deposited, but cell-line/organoid authentication and mycoplasma testing are not reported, and antibody details are largely absent.

Evidence

paraphrase[Results, LXR inverse agonists lower TG and cholesterol]

“Information on these compounds is available in patent US11970484B2 (ref. ; Supplementary Fig.).”

“PK parameters were estimated via noncompartmental methods using Pheonix WinNonlin 6.2.1 and 8.3.4 (Certara).”

Statistical analysisFind in source

absence[Methods, Preclinical studies]

Mycoplasma testing and cell-line authentication are not reported.

PASSReviewer 2· 80% conf

The investigational product (TLC-2716) is named with doses and route, analysis software is identified with versions, and key data (HLO RNA-seq) are deposited under an accession; primer sequences are provided in supplementary material.

Evidence

“TLC-2716 0.5, 2, 6 or 12 mg (eight participants per dose) orally once daily for 14 days”

AbstractFind in source

“PK parameters were estimated via noncompartmental methods using Pheonix WinNonlin 6.2.1 and 8.3.4 (Certara).”

MethodsFind in source

“The HLO RNA-sequencing data are available under GEO number GSE299888”

Data availabilityFind in source

FAILReviewer 3· 75% conf

Key biological resources are inadequately identified; only software tools are fully reported, while cell line authentication, mycoplasma testing, and reagent identification are lacking.

Evidence

absence[Methods, Human liver organoids]

Cell line authentication is not reported for HLOs.

absence[Methods, Cell culture]

Mycoplasma testing is not mentioned.

“PK parameters were estimated via noncompartmental methods using Pheonix WinNonlin 6.2.1 and 8.3.4 (Certara).”

Statistical analysisFind in source

All statistical tests are named (e.g., Mann-Whitney U, Wilcoxon signed-rank, BH adjustment); exact p-values are provided in tables and figures; effect sizes (Hodges-Lehmann estimators) with 95% CIs are reported; software is identified; individual data points are shown in dot plots with defined error bars and per-group n. Assumption verification is adequate given the use of non-parametric tests for the clinical data.

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityPASS

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 75% conf

Statistical methods are thoroughly named, the skewed-data handling is explicitly justified via nonparametric tests and the Hodges–Lehmann estimator, exact p-values and effect sizes with 95% CIs are reported, and software is identified.

Evidence

paraphrase[Methods, Statistical analyses]

“two-tailed Wilcoxon signed-rank tests (for comparisons within groups) and two-tailed Mann–Whitney U-tests (for comparisons between groups) were used, which were adjusted using the BH adjustment method.”

“we applied the Hodges–Lehmann estimator in deriving placebo-adjusted percentage change from baseline values in lipid parameters.”

Statistical analysisFind in source

paraphrase[Table 1]

“P value versus placebo b — | 0.281 | 0.681 | 0.003 | 0.024”

PASSReviewer 2· 85% conf

Statistical tests are explicitly named with corrections, exact p-values with 95% CIs are reported for the key lipid endpoints, software is identified, and per-group n and CONSORT flow are provided.

Evidence

“two-tailed Wilcoxon signed-rank tests (for comparisons within groups) and two-tailed Mann–Whitney U -tests (for comparisons between groups) were used, which were adjusted using the BH adjustment method.”

Statistical analysisFind in source

“Placebo-adjusted percentage change from day 1 to day 14 a | — | −14.9 (−39.9, 6.2) | −3.7 (−34.3, 23.9) | −37.6 (−54.0, −19.9) | −38.5 (−67.9, −7.2) | | P value versus placebo b | — | 0.281 | 0.681 | 0.003 | 0.024”

Table 1Find in source

“Data are shown as mean (s.d.) or mean (95% CI).”

Table 1Find in source

PASSReviewer 3· 90% conf

Statistical analysis is robustly reported with named tests, exact p-values, effect sizes with confidence intervals, identified software, and clear data presentation.

Evidence

paraphrase[Methods, Phase 1 clinical trial, Statistical analyses]

“For analyses of changes from baseline, two-tailed Wilcoxon signed-rank tests (for comparisons within groups) and two-tailed Mann–Whitney U-tests (for comparisons between groups) were used, which were adjusted using the BH adjustment method.”

paraphrase[Table 1]

“P value versus placebo: 0.003”

paraphrase[Table 1]

“Placebo-adjusted percentage change from day 1 to day 14: −37.6 (−54.0, −19.9)”

The data-availability statement specifies that individual phase 1 patient data are available 'upon reasonable request from academic or qualified clinical researchers affiliated with recognized institutions' with submitted proposal/CV/declaration and a signed data-access agreement — a concrete managed-access mechanism, which is the field norm for IPD. Preclinical raw data and trial summary results are in Source Data. HLO RNA-seq is deposited at GEO (GSE299888), and dbGaP accession (phs002453.v1.p1) is cited for the MVP data. Code availability states 'This study did not generate original code.'

Sub-criteria

code sharingADEQUATE

accession numbersADEQUATE

repository depositADEQUATE

data availability statementADEQUATE

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 80% conf

A detailed data-availability statement provides a concrete managed-access mechanism for the individual patient data, the HLO RNA-seq data are deposited with a GEO accession, and the no-original-code statement is explicit.

Evidence

“The HLO RNA-sequencing data are available under GEO number GSE299888”

Data availabilityFind in source

paraphrase[Data availability]

“the individual data from the phase 1 clinical trial are available upon reasonable request from academic or qualified clinical researchers affiliated with recognized institutions... Applicants are required to submit a detailed research proposal, curriculum vitae and declaration of non-conflict of interest.”

“This study did not generate original code.”

Data availabilityFind in source

PASSReviewer 2· 85% conf

A data-availability statement with a concrete managed-access mechanism for individual patient data is present, raw preclinical data and summary trial results are in Source Data, HLO RNA-seq is deposited in GEO, and code availability is addressed.

Evidence

“the individual data from the phase 1 clinical trial are available upon reasonable request from academic or qualified clinical researchers affiliated with recognized institutions, strictly for the purpose of conducting noncommercial, ethically approvable research”

Data availabilityFind in source

“The HLO RNA-sequencing data are available under GEO number GSE299888”

Data availabilityFind in source

“This study did not generate original code.”

Data availabilityFind in source

PASSReviewer 3· 85% conf

Data availability is adequately stated with a concrete access route for clinical data and a GEO deposit for organoid RNA-seq data; code sharing is not applicable.

Evidence

“the individual data from the phase 1 clinical trial are available upon reasonable request from academic or qualified clinical researchers affiliated with recognized institutions, strictly for the purpose of conducting noncommercial, ethically approvable research aligned with the original scope of the trial.”

Data availabilityFind in source

paraphrase[Data availability]

“The HLO RNA-sequencing data are available under GEO number GSE299888.”

“This study did not generate original code.”

Data availabilityFind in source

All seven sub-criteria are met. The clinical trial is registered (NCT05483998), a CONSORT checklist is provided, methods are comprehensive, all outcomes are reported, limitations are discussed, conclusions are appropriately cautious, and competing interests are declared.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 80% conf

The trial is registered (NCT05483998), a CONSORT checklist is provided, methods are detailed, limitations are acknowledged, and funding/competing-interest statements are present.

Evidence

“ClinicalTrials.gov identifier: NCT05483998”

AbstractFind in source

“Supplementary Fig. 1. Blank copy of the informed consent, approved study protocol for phase 1 clinical trial and CONSORT checklist.”

Supplementary materialFind in source

“Although these data must be interpreted cautiously due to our evaluation of healthy volunteers and multiple exploratory endpoints”

DiscussionFind in source

PASSReviewer 2· 85% conf

Methods are detailed, the trial is registered (NCT05483998), a CONSORT checklist is provided, all outcomes are reported, limitations are discussed, conclusions are appropriately cautious, and a competing-interests statement is present.

Evidence

“ClinicalTrials.gov identifier: NCT05483998”

AbstractFind in source

“Although these data must be interpreted cautiously due to our evaluation of healthy volunteers and multiple exploratory endpoints”

DiscussionFind in source

“A.V., R.S.H., S.W., E.M., B.J.K., R.P.M. and G.M.S. are employed by OrsoBio”

Competing interestsFind in source

PASSReviewer 3· 95% conf

Reporting is complete and transparent: methods are detailed, trial is registered, reporting guidelines are followed, outcomes are fully reported, limitations are discussed, conclusions are proportional, and funding/COI are disclosed.

Evidence

“ClinicalTrials.gov identifier: NCT05483998”

AbstractFind in source

“Although these data must be interpreted cautiously due to our evaluation of healthy volunteers and multiple exploratory endpoints”

Discussion ¶7Find in source

“A.V., R.S.H., S.W., E.M., B.J.K., R.P.M. and G.M.S. are employed by OrsoBio, and J.A. and T.T. are advisors to OrsoBio.”

Competing interestsFind in source

Registered (2 IDs: ClinicalTrials.gov). Reporting guideline cited: CONSORT.

Broken references and links

None found

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Checked — nothing surfaced.

7 data/code links checked; 7 live.

Copyediting

7 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 7 minor suggestions below.

7 copyedit issues flagged: mostly consistency, clarity, punctuation.

Kaimen Rigor Action ItemsFinal pass before journal submission

This published work demonstrates good scientific premise and robust statistical reporting. However, an informed reader should weigh the significant reporting gaps in preclinical study design, biological variables, and ethical approvals (specifically, the absence of animal ethics statements). These omissions, along with the misidentified HepG2 cell line, suggest areas where an erratum or independent re-analysis might be warranted to enhance the robustness and reproducibility of the preclinical findings.

1.
HIGHother
Address the misidentification of the HepG2 cell line (CURATED-0001) by either providing authentication (e.g., STR profiling) for the stock used or acknowledging the potential impact of using a misidentified cell type.
The HepG2 cell line is listed as misidentified in the ICLAC register, which could mean results attributed to it describe a different cell type, impacting the validity of findings.
2.
HIGHethics
Add an animal-welfare (IACUC or equivalent) approval statement, ideally with institution and protocol number, for all rodent and NHP efficacy/toxicology studies in the Methods section.
The absence of an animal ethics statement is a significant reporting gap for extensive animal research and is a core requirement for ethical transparency.
3.
HIGHrigor
Report the randomization method (e.g., computer-generated random numbers, block randomization) for the clinical trial in the Methods, Phase 1 clinical trial / Study design section.
The method of randomization is crucial for assessing the internal validity and preventing selection bias in a clinical trial.
4.
HIGHrigor
State whether the clinical trial was blinded (double-blind, single-blind, or open-label) and provide a rationale if open-label, in the Methods, Phase 1 clinical trial section.
Blinding status is essential for evaluating potential bias in a placebo-controlled clinical trial.
5.
HIGHrigor
Provide a scientific justification for the use of a single sex (male) in the rodent efficacy studies, or include both sexes, in the Methods, In vivo studies section.
Reporting and justifying the sex of animals used is critical for generalizability and reproducibility of preclinical findings.
6.
HIGHrigor
Add cell-line/organoid authentication (e.g., STR profiling or donor verification) and a mycoplasma-testing statement for the HLO/sHLO work in the Methods section.
Authentication and mycoplasma testing are standard quality control measures for cell lines and organoids, ensuring the reliability of in vitro results.
7.
MEDIUMreporting
Name a recognized human-research compliance framework (e.g., Declaration of Helsinki, ICH-GCP) in Methods, Study oversight, rather than only 'relevant local regulatory policies'.
Citing a specific, recognized framework enhances the transparency and international applicability of ethical compliance.
8.
MEDIUMrigor
Report animal age, weight, and housing/husbandry conditions (light cycle, temperature, enrichment) for the preclinical studies in the Methods section.
Detailed reporting of animal characteristics and housing conditions is essential for reproducibility and interpretation of preclinical results.
9.
MEDIUMreporting
Report human race/ethnicity in the baseline demographics table (Fig. 4 / Table 1) to complete the demographic description.
Complete demographic reporting, including race/ethnicity, is important for assessing generalizability and potential disparities in clinical trial populations.
10.
MEDIUMcopyedit
Clarify the total placebo count in Methods, Study design, to reconcile the statement 'two participants per dose' with Table 1's n=10 for placebo.
Internal numerical inconsistencies can confuse readers and undermine confidence in the reported data.
11.
MEDIUMcopyedit
Standardize p-value precision in Table 1 (e.g., a single reported value '0.006' vs '0.0058' for numerically identical VLDL-C and RC-predose rows) to avoid apparent inconsistencies.
Consistent reporting of numerical precision improves clarity and avoids misleading readers about the underlying data.
12.
MEDIUMcopyedit
Correct the punctuation in Table 1, Small LDL particles row, by inserting a comma: '−34.5 (−80.6, 21.5)'.
Missing punctuation can hinder readability and misrepresent numerical ranges.
13.
LOWcopyedit
Complete the sentence in the Data availability section: 'The study protocol and statistical plan are available within the article and .' by providing the actual location or accession.
An incomplete sentence fragment indicates a missing reference or link, which should be resolved for clarity.
14.
LOWcopyedit
Define LXRβ as 'liver X receptor beta' at first use in the extended data legends (e.g., Extended Data Fig. 1 legend).
Defining abbreviations in all relevant sections ensures clarity for readers who may not read the main text first.
15.
LOWcopyedit
Consider adding a brief explanation of the Hodges-Lehmann estimator in the Table 1 footnote for readers unfamiliar with non-parametric methods.
Providing context for specialized statistical terms enhances accessibility for a broader audience.

Full text (91,838 chars · analyzed ~82%, head + tail)Analyzed: Aug 10, 2026

Start the discussion on JRNLClub

Community discussion on jrnlclub.com

Read alongside

An oral, liver-restricted LXR inverse agonist for dyslipidemia: preclinical development and phase 1 trial.

Li X, Benegiamo G, Vijayakumar A, Sroda N, Kimura M, Huss RS, Weng S, Murakami E, Kirby BJ, von Alvensleben GVG, Kremoser C, Gane EJ, Takebe T, Myers RP, Subramanian GM, Auwerx J

Read full text (PMC)

DOI

10.1038/s41591-025-04169-6

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/b029c5f1-725e-4936-835a-17129b2d08b3" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/b029c5f1-725e-4936-835a-17129b2d08b3/badge" alt="Kaimen Rigor review — 1★ (Critical), 0 critical, 6 high issues for “An oral, liver-restricted LXR inverse agonist for dyslipidemia: preclinical development and phase 1 trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

2a73b286fe4107c51fb52e9f314000eba38190a51ddc360d0311407ce202d970

Verify via API

Issued Aug 10, 2026Engine 7.29.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Kaimen Rigor review

Kaimen Rigor reviewed

1 / 5

Critical — serious problems across many checks

Mixed Methods

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×4−2★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ReportingBiological variables not met−0.5★
ReportingKey resources not met−0.5★
ReportingStudy design partially met−0.25★
ReportingEthical approvals partially met−0.25★

Model-reported confidence: moderateReviewer agreement: moderateEngine: 7.29.0Source: full text

Not verified in this report

References were not verified against Crossref/OpenAlex.
Statistics were not checked: no recomputable values were found in this text — no test statistic reported with its degrees of freedom, no effect estimate printed with both a 95% CI and a p-value, and no percentage printed with both its count and its denominator.

Biggest issues

01Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The efficacy claim is based on reduction in plasma lipids (TG, RC, LDL-C) which are surrogate biomarkers. The paper shows target engagement (reduction in LXR target genes, ApoC3, ANGPTL3) but does not cite validated evidence that these lipid changes are linked to improved clinical outcomes (e.g., reduced cardiovascular events).
“TLC-2716 treatment for 14 days led to dose-dependent improvements in plasma TG and RC and other atherogenic lipids”
Find in source
02Biological variables not reported
highDisclosurereviewer-assessedFull detail
Biological variables are inadequately reported across both preclinical and clinical components, with no sub-criterion fully met due to missing details on animal sex, age, housing, and human demographics.
03Key resources not identified
highDisclosurereviewer-assessedFull detail
Key biological resources are inadequately identified; only software tools are fully reported, while cell line authentication, mycoplasma testing, and reagent identification are lacking.
“PK parameters were estimated via noncompartmental methods using Pheonix WinNonlin 6.2.1 and 8.3.4 (Certara).”
Statistical analysisFind in source
04Other integrity concern
mediumAuthenticityreviewer-assessedFull detail
Trial NCT06564584 was first submitted to ClinicalTrials.gov on 2024-08-19, after the registered study start date of 2024-08-12. Retrospective registration means the protocol and outcomes were not on the public record before the study ran, which is what prospective registration exists to establish.
NCT06564584
reviewer’s wording
05Other integrity concern
mediumAuthenticityreviewer-assessedFull detail
Cell line "HepG2" is on the ICLAC register (CURATED-0001) as misidentified (Liver, hepatoblastoma), not Liver, hepatocellular carcinoma. Results attributed to this line may describe a different cell type unless the stock was authenticated (e.g. STR profiling).
“1 and SREBP1c luciferase reporter assays HT-29 or HepG2 cells were stably transfected with pGL4 luciferase reporter plasmid c”
Find in source

Findings by category

101ArithmeticNumerical inconsistencies 202OverreachOverstated conclusions 103AuthenticityData authenticity concerns 404DisclosureReporting gaps 05AvailabilityNone found 06Copyedit7 minor suggestions

Numerical inconsistencies

1 finding · worst low

Internal contradictions in the reported numbersAssessed

Overstated conclusions

2 findings · worst high

Efficacy rests on an unvalidated surrogate endpointAssessed
Conclusions only partially backed by the presented evidenceAssessed

12 major claims checked against the paper's own evidence: all adequately supported.

Premise concern: surrogate not validated for clinical benefit.

Data authenticity concerns

1 finding · worst medium

Other integrity concernAssessed

4 integrity concerns flagged (0 high).

Reporting gaps

4 findings · worst high

Biological variables not reportedAssessed
Key resources not identifiedAssessed
Ethics/consent reporting incompleteAssessed
Study-design details incomplete (controls, blinding, power)Assessed

Eight Dimensions4 pass · 2 warn · 2 fail

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 90% conf

Evidence

“Given concerns that systemic LXR repression may impair reverse cholesterol transport, we developed TLC-2716, an orally administered, gut- and liver-restricted LXR inverse agonist.”

AbstractFind in source

“However, to date, no LXR inverse agonist has been evaluated in humans.”

IntroductionFind in source

paraphrase[Introduction]

“Paraphrase: The introduction cites numerous prior studies on LXR activation raising TG/LDL-C, LXR inverse agonists in preclinical models, and the risk of impaired RCT.”

PASSReviewer 2· 90% conf

Evidence

paraphrase[Introduction, paragraph 2]

“Repression of LXR systemically carries potential risks, including the impairment of reverse cholesterol transport (RCT)... which could promote atherogenesis”

“However, to date, no LXR inverse agonist has been evaluated in humans.”

Introduction ¶3Find in source

PASSReviewer 3· 95% conf

The scientific premise is well-established with thorough citations of prior work, a clear logical rationale for the study, and explicit acknowledgment of limitations of prior approaches.

Evidence

paraphrase[Introduction, paragraph 5]

“LXR activation increases liver and plasma TG and LDL-C in animal models and humans by upregulating DNL genes... By contrast, repression of LXR activity in the liver reduces hepatic DNL...”

“Given concerns that systemic LXR repression may impair reverse cholesterol transport, we developed TLC-2716, an orally administered, gut- and liver-restricted LXR inverse agonist.”

Introduction ¶6Find in source

paraphrase[Abstract]

Sub-criteria

controlsN/A

power analysisINADEQUATE

blinding levelsNOT REPORTED

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodINADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (3) — the votes behind the verdict

WARNReviewer 1· 60% conf

Evidence

“Participants were randomized to receive either placebo (two participants per dose) or TLC-2716 0.5, 2, 6 or 12 mg (eight participants per dose) orally once daily for 14 days.”

MethodsFind in source

“Due to its exploratory nature, no formal power or sample size calculations were used to determine the sample size for this study.”

Statistical analysisFind in source

absence[Methods, Phase 1 clinical trial]

Blinding is not reported anywhere in the manuscript.

WARNReviewer 2· 80% conf

Evidence

“Participants were randomized to receive either placebo (two participants per dose) or TLC-2716 0.5, 2, 6 or 12 mg (eight participants per dose) orally once daily for 14 days.”

MethodsFind in source

“Due to its exploratory nature, no formal power or sample size calculations were used to determine the sample size for this study.”

Statistical analysisFind in source

“Given the skewed distribution of plasma lipid data, we applied the Hodges–Lehmann estimator in deriving placebo-adjusted percentage change from baseline values in lipid parameters.”

Statistical analysisFind in source

FAILReviewer 3· 85% conf

Evidence

“The randomized, placebo-controlled phase 1 study included SAD and MAD cohorts.”

MethodsFind in source

absence[Methods, Phase 1 clinical trial]

No blinding is mentioned for the clinical trial.

“Due to its exploratory nature, no formal power or sample size calculations were used to determine the sample size for this study.”

Statistical analysisFind in source

Sub-criteria

demographicsNOT REPORTED

sex reportedINADEQUATE

sex justifiedNOT REPORTED

age weight healthINADEQUATE

housing conditionsNOT REPORTED

species strain sourceINADEQUATE

Per reviewer (3) — the votes behind the verdict

WARNReviewer 1· 60% conf

Evidence

paraphrase[Methods, Inclusion and exclusion criteria]

“eligible study participants were healthy, nonsmoking men and women between 18 and 55 years of age and with a BMI from 19 to 35 kg m-2”

paraphrase[Results / Methods]

“Paraphrase: Rodent models are identified as HFD-DIO mice, HFD-fed ZDF rats, HFD-fed SD rats, Wistar Han rats, CD-1 mice, PXB humanized-liver mice, and cynomolgus monkeys.”

absence[Methods]

Animal housing/husbandry conditions and age/weight are not reported.

PASSReviewer 2· 75% conf

Sex, age and BMI of human participants are reported with both sexes enrolled; demographics omit race/ethnicity, and sex was not used in the analysis due to small group sizes.

Evidence

paraphrase[Methods, Inclusion and exclusion criteria]

“eligible study participants were healthy, nonsmoking men and women between 18 and 55 years of age and with a BMI from 19 to 35 kg m−2”

“In this clinical trial study, sex is self-reported. Due to the small sample size of each group, sex is not considered in the analysis.”

Statistical analysisFind in source

FAILReviewer 3· 70% conf

Evidence

paraphrase[Fig. 4b,c]

“Baseline characterization of healthy participants enrolled in SAD and MAD cohorts... Male, n (%)”

paraphrase[Methods, Phase 1 clinical trial, Inclusion and exclusion criteria]

“eligible study participants were healthy, nonsmoking men and women between 18 and 55 years of age and with a BMI from 19 to 35 kg m−2”

absence[Methods, Animal experiments]

Housing conditions for animals are not reported.

Sub-criteria

iacuc statementNOT REPORTED

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (3) — the votes behind the verdict

WARNReviewer 1· 65% conf

Evidence

“The study protocol was approved by the Northern B Health and Disability Ethics Committee (2022 FULL 12858).”

MethodsFind in source

“Written informed consent was obtained before enrollment.”

MethodsFind in source

absence[Methods, Preclinical studies]

No animal-welfare (IACUC) approval statement is present for the rodent/NHP studies.

WARNReviewer 2· 80% conf

Evidence

“The study protocol was approved by the Northern B Health and Disability Ethics Committee (2022 FULL 12858).”

MethodsFind in source

“Written informed consent was obtained before enrollment.”

MethodsFind in source

“conducted at a single site in New Zealand (Auckland Clinical Research) from 27 July 2022 to 18 June 2023, in accordance with relevant local regulatory policies.”

MethodsFind in source

WARNReviewer 3· 90% conf

Human ethics and consent are adequately reported, but the animal IACUC statement is missing, which warrants a warning.

Evidence

“The study protocol was approved by the Northern B Health and Disability Ethics Committee (2022 FULL 12858).”

MethodsFind in source

“Written informed consent was obtained before enrollment.”

MethodsFind in source

absence[Methods, Animal experiments]

IACUC approval for animal experiments is not stated.

Sub-criteria

mycoplasma testingNOT REPORTED

reagents identifiedINADEQUATE

organisms identifiedINADEQUATE

antibodies identifiedN/A

cell line authenticationNOT REPORTED

software tools identifiedADEQUATE

Per reviewer (3) — the votes behind the verdict

WARNReviewer 1· 55% conf

Evidence

paraphrase[Results, LXR inverse agonists lower TG and cholesterol]

“Information on these compounds is available in patent US11970484B2 (ref. ; Supplementary Fig.).”

“PK parameters were estimated via noncompartmental methods using Pheonix WinNonlin 6.2.1 and 8.3.4 (Certara).”

Statistical analysisFind in source

absence[Methods, Preclinical studies]

Mycoplasma testing and cell-line authentication are not reported.

PASSReviewer 2· 80% conf

Evidence

“TLC-2716 0.5, 2, 6 or 12 mg (eight participants per dose) orally once daily for 14 days”

AbstractFind in source

“PK parameters were estimated via noncompartmental methods using Pheonix WinNonlin 6.2.1 and 8.3.4 (Certara).”

MethodsFind in source

“The HLO RNA-sequencing data are available under GEO number GSE299888”

Data availabilityFind in source

FAILReviewer 3· 75% conf

Key biological resources are inadequately identified; only software tools are fully reported, while cell line authentication, mycoplasma testing, and reagent identification are lacking.

Evidence

absence[Methods, Human liver organoids]

Cell line authentication is not reported for HLOs.

absence[Methods, Cell culture]

Mycoplasma testing is not mentioned.

“PK parameters were estimated via noncompartmental methods using Pheonix WinNonlin 6.2.1 and 8.3.4 (Certara).”

Statistical analysisFind in source

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityPASS

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 75% conf

Evidence

paraphrase[Methods, Statistical analyses]

“we applied the Hodges–Lehmann estimator in deriving placebo-adjusted percentage change from baseline values in lipid parameters.”

Statistical analysisFind in source

paraphrase[Table 1]

“P value versus placebo b — | 0.281 | 0.681 | 0.003 | 0.024”

PASSReviewer 2· 85% conf

Statistical tests are explicitly named with corrections, exact p-values with 95% CIs are reported for the key lipid endpoints, software is identified, and per-group n and CONSORT flow are provided.

Evidence

“two-tailed Wilcoxon signed-rank tests (for comparisons within groups) and two-tailed Mann–Whitney U -tests (for comparisons between groups) were used, which were adjusted using the BH adjustment method.”

Statistical analysisFind in source

Table 1Find in source

“Data are shown as mean (s.d.) or mean (95% CI).”

Table 1Find in source

PASSReviewer 3· 90% conf

Statistical analysis is robustly reported with named tests, exact p-values, effect sizes with confidence intervals, identified software, and clear data presentation.

Evidence

paraphrase[Methods, Phase 1 clinical trial, Statistical analyses]

paraphrase[Table 1]

“P value versus placebo: 0.003”

paraphrase[Table 1]

“Placebo-adjusted percentage change from day 1 to day 14: −37.6 (−54.0, −19.9)”

Sub-criteria

code sharingADEQUATE

accession numbersADEQUATE

repository depositADEQUATE

data availability statementADEQUATE

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 80% conf

Evidence

“The HLO RNA-sequencing data are available under GEO number GSE299888”

Data availabilityFind in source

paraphrase[Data availability]

“This study did not generate original code.”

Data availabilityFind in source

PASSReviewer 2· 85% conf

Evidence

“the individual data from the phase 1 clinical trial are available upon reasonable request from academic or qualified clinical researchers affiliated with recognized institutions, strictly for the purpose of conducting noncommercial, ethically approvable research”

Data availabilityFind in source

“The HLO RNA-sequencing data are available under GEO number GSE299888”

Data availabilityFind in source

“This study did not generate original code.”

Data availabilityFind in source

PASSReviewer 3· 85% conf

Data availability is adequately stated with a concrete access route for clinical data and a GEO deposit for organoid RNA-seq data; code sharing is not applicable.

Evidence

“the individual data from the phase 1 clinical trial are available upon reasonable request from academic or qualified clinical researchers affiliated with recognized institutions, strictly for the purpose of conducting noncommercial, ethically approvable research aligned with the original scope of the trial.”

Data availabilityFind in source

paraphrase[Data availability]

“The HLO RNA-sequencing data are available under GEO number GSE299888.”

“This study did not generate original code.”

Data availabilityFind in source

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 80% conf

The trial is registered (NCT05483998), a CONSORT checklist is provided, methods are detailed, limitations are acknowledged, and funding/competing-interest statements are present.

Evidence

“ClinicalTrials.gov identifier: NCT05483998”

AbstractFind in source

“Supplementary Fig. 1. Blank copy of the informed consent, approved study protocol for phase 1 clinical trial and CONSORT checklist.”

Supplementary materialFind in source

“Although these data must be interpreted cautiously due to our evaluation of healthy volunteers and multiple exploratory endpoints”

DiscussionFind in source

PASSReviewer 2· 85% conf

Evidence

“ClinicalTrials.gov identifier: NCT05483998”

AbstractFind in source

“Although these data must be interpreted cautiously due to our evaluation of healthy volunteers and multiple exploratory endpoints”

DiscussionFind in source

“A.V., R.S.H., S.W., E.M., B.J.K., R.P.M. and G.M.S. are employed by OrsoBio”

Competing interestsFind in source

PASSReviewer 3· 95% conf

Evidence

“ClinicalTrials.gov identifier: NCT05483998”

AbstractFind in source

“Although these data must be interpreted cautiously due to our evaluation of healthy volunteers and multiple exploratory endpoints”

Discussion ¶7Find in source

“A.V., R.S.H., S.W., E.M., B.J.K., R.P.M. and G.M.S. are employed by OrsoBio, and J.A. and T.T. are advisors to OrsoBio.”

Competing interestsFind in source

Registered (2 IDs: ClinicalTrials.gov). Reporting guideline cited: CONSORT.

Broken references and links

None found

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Checked — nothing surfaced.

7 data/code links checked; 7 live.

Copyediting

7 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 7 minor suggestions below.

7 copyedit issues flagged: mostly consistency, clarity, punctuation.

Kaimen Rigor Action ItemsFinal pass before journal submission

1.
HIGHother
Address the misidentification of the HepG2 cell line (CURATED-0001) by either providing authentication (e.g., STR profiling) for the stock used or acknowledging the potential impact of using a misidentified cell type.
The HepG2 cell line is listed as misidentified in the ICLAC register, which could mean results attributed to it describe a different cell type, impacting the validity of findings.
2.
HIGHethics
Add an animal-welfare (IACUC or equivalent) approval statement, ideally with institution and protocol number, for all rodent and NHP efficacy/toxicology studies in the Methods section.
The absence of an animal ethics statement is a significant reporting gap for extensive animal research and is a core requirement for ethical transparency.
3.
HIGHrigor
Report the randomization method (e.g., computer-generated random numbers, block randomization) for the clinical trial in the Methods, Phase 1 clinical trial / Study design section.
The method of randomization is crucial for assessing the internal validity and preventing selection bias in a clinical trial.
4.
HIGHrigor
State whether the clinical trial was blinded (double-blind, single-blind, or open-label) and provide a rationale if open-label, in the Methods, Phase 1 clinical trial section.
Blinding status is essential for evaluating potential bias in a placebo-controlled clinical trial.
5.
HIGHrigor
Provide a scientific justification for the use of a single sex (male) in the rodent efficacy studies, or include both sexes, in the Methods, In vivo studies section.
Reporting and justifying the sex of animals used is critical for generalizability and reproducibility of preclinical findings.
6.
HIGHrigor
Add cell-line/organoid authentication (e.g., STR profiling or donor verification) and a mycoplasma-testing statement for the HLO/sHLO work in the Methods section.
Authentication and mycoplasma testing are standard quality control measures for cell lines and organoids, ensuring the reliability of in vitro results.
7.
MEDIUMreporting
Name a recognized human-research compliance framework (e.g., Declaration of Helsinki, ICH-GCP) in Methods, Study oversight, rather than only 'relevant local regulatory policies'.
Citing a specific, recognized framework enhances the transparency and international applicability of ethical compliance.
8.
MEDIUMrigor
Report animal age, weight, and housing/husbandry conditions (light cycle, temperature, enrichment) for the preclinical studies in the Methods section.
Detailed reporting of animal characteristics and housing conditions is essential for reproducibility and interpretation of preclinical results.
9.
MEDIUMreporting
Report human race/ethnicity in the baseline demographics table (Fig. 4 / Table 1) to complete the demographic description.
Complete demographic reporting, including race/ethnicity, is important for assessing generalizability and potential disparities in clinical trial populations.
10.
MEDIUMcopyedit
Clarify the total placebo count in Methods, Study design, to reconcile the statement 'two participants per dose' with Table 1's n=10 for placebo.
Internal numerical inconsistencies can confuse readers and undermine confidence in the reported data.
11.
MEDIUMcopyedit
Standardize p-value precision in Table 1 (e.g., a single reported value '0.006' vs '0.0058' for numerically identical VLDL-C and RC-predose rows) to avoid apparent inconsistencies.
Consistent reporting of numerical precision improves clarity and avoids misleading readers about the underlying data.
12.
MEDIUMcopyedit
Correct the punctuation in Table 1, Small LDL particles row, by inserting a comma: '−34.5 (−80.6, 21.5)'.
Missing punctuation can hinder readability and misrepresent numerical ranges.
13.
LOWcopyedit
Complete the sentence in the Data availability section: 'The study protocol and statistical plan are available within the article and .' by providing the actual location or accession.
An incomplete sentence fragment indicates a missing reference or link, which should be resolved for clarity.
14.
LOWcopyedit
Define LXRβ as 'liver X receptor beta' at first use in the extended data legends (e.g., Extended Data Fig. 1 legend).
Defining abbreviations in all relevant sections ensures clarity for readers who may not read the main text first.
15.
LOWcopyedit
Consider adding a brief explanation of the Hodges-Lehmann estimator in the Table 1 footnote for readers unfamiliar with non-parametric methods.
Providing context for specialized statistical terms enhances accessibility for a broader audience.

Full text (91,838 chars · analyzed ~82%, head + tail)Analyzed: Aug 10, 2026